Imaging That Can Reliably Distinguish Between Benign And Malignant Pancreatic Cysts
Optical Coherence Tomography (OCT) has been demonstrated to be able to differentiate between benign and potentially malignant pancreatic cysts. Researchers from Massachusetts General Hospital, Physical Sciences, Inc., Brigham and Women’s Hospital, and Brandeis University have published their findings in Biomedical Optics Express. In their study they used surgically removed pancreas specimens of patients with pancreatic cysts to assess them with OCT and compare the results with histology examinations. OCT was able to reveal specific morphological characteristics used to differentiate between the low-risk and high-risk cysts. Read more »
*This blog post was originally published at Medgadget*
A technique to identify myelination in order to map the layout of cortical areas in the human brain has been developed by researchers led by David van Essen at the Washington University School of Medicine in St. Louis. It is generally known that myelination levels are different throughout the cerebral cortex. The best way to assess it is to investigate the brain post mortem. Using the new technique of myelination mapping, it will be possible to accurately map individual cortical areas in vivo. The researchers used their method on a group of control subjects and found an excellent agreement between the spatial gradients of the myelin maps and already published anatomical and functional information about cortical areas, mostly based on post-mortem histology.
It seems intuitive (at least to Medgadgeteers) that mobile technology can be used to improve health outcomes, but we still need studies to actually put data behind this idea. A recent study of the DiabetesManager mobile health platform from WellDoc is a step in this direction. We 
Researchers from Columbia University have developed a “lab on a chip” HIV and syphilis test, and are now reporting the first results from tests in the field conducted in Rwanda. The mChip, as it is called, is the size of a credit card and replicates all steps of an ELISA test, at a lower total material cost and within 20 minutes. After application of a blood sample, the chip is inserted into a $100 battery-powered handheld analyzer. It needs only 1 μl of unprocessed whole blood and does not require any user interpretation of the signal, providing a clear-cut yes or no result.
